Purine biosynthesis pathway enzyme

Purine biosynthesis pathway enzymes collectively refer to the series of enzymes responsible for the stepwise construction of purine nucleotides from basic precursors. The canonical pathway synthesizes inosine monophosphate (IMP), a precursor to adenine (AMP) and guanine (GMP) nucleotides, through ten enzymatic steps. These enzymes include amidotransferases, transferases, synthases, and ligases such as phosphoribosyl pyrophosphate amidotransferase (PPAT), glycinamide ribonucleotide synthetase (GARS), phosphoribosyl formylglycinamidine synthase (FGAMS), adenylosuccinate lyase (ASL), and others. Some, like GART, PAICS, and ATIC, are multifunctional, containing multiple enzymatic domains[1][4]. These enzymes are tightly regulated, both allosterically and via feedback inhibition by nucleotide products. They are essential for the generation of purine nucleotides, which serve as building blocks for DNA and RNA and as energy carriers (ATP, GTP), regulatory molecules, and signaling mediators in cells[2][3][4][5]. In rapidly dividing cells, such as in cancer or certain immune responses, purine biosynthesis is especially active, making the pathway a critical target for chemotherapeutic, immunosuppressive, and antiviral drugs[4][2]. Disruption of this pathway can cause immune deficiency, neurological syndromes, or gout, and measuring purine metabolites or enzyme expression can serve as biomarkers for disease or therapy response. Note: This target entry is **incorrect in its original form**. "Purine synthesis pathway enzymes" is a **group of enzymes, not a distinct molecular entity**. Each specific enzyme (e.g. phosphoribosyl pyrophosphate amidotransferase, IMP dehydrogenase) should be treated as a separate target. For structured data, individual enzymes from this pathway should be listed and annotated.

Other names

Purine synthesis enzymePurine biosynthetic enzymede novo purine biosynthetic enzymePur pathway enzyme

Inhibition of specific pathway enzymes to block purine biosynthesis (e.g., PPAT, IMPDH, ATIC); Antimetabolite action (incorporation of analogs that disrupt the pathway); Depletion of nucleotide pools; Allosteric inhibition or feedback inhibition of pathway enzymes